Sunday 22 December 2024

The Pharma Letter Podcast — Episode 23 — AAIC preview with Eisai deputy CCO Michael Irizarry

Biotechnology
Simon Wentworth
6 July 2023
podcast-23-large

More on this story...

Pharmaceutical
Data disaster casts cloud over BioXcel's Alzheimer's agitation results
29 June 2023
Biotechnology
BRIEF—AAIC 2023: Prothena offers data on BMS-partnered antibody
12 July 2023
Biotechnology
New Alzheimer's therapies ready for battle at AAIC 2023
12 July 2023
Pharmaceutical
BRIEF—Eisai divest two drugs to Kaken
29 March 2024


Companies featured in this story

More ones to watch >


Today's issue

Neurocrine Biosciences launches Crenessity in USA
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024
Pharmaceutical
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Biotechnology
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024
Biotechnology
Novartis to shut MorphSys sites amid pelabresib delay
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Biotechnology

Epitopea teams up with Genevant in $124 million deal
20 December 2024
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Regeneron advances anticoagulant antibody program
20 December 2024
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze